Pediatric Rheumatology

Papers
(The H4-Index of Pediatric Rheumatology is 18. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2020-03-01 to 2024-03-01.)
ArticleCitations
Juvenile idiopathic arthritis: from aetiopathogenesis to therapeutic approaches81
Defining Kawasaki disease and pediatric inflammatory multisystem syndrome-temporally associated to SARS-CoV-2 infection during SARS-CoV-2 epidemic in Italy: results from a national, multicenter survey69
Consensus treatment plans for periodic fever, aphthous stomatitis, pharyngitis and adenitis syndrome (PFAPA): a framework to evaluate treatment responses from the childhood arthritis and rheumatology 37
Proceedings of the 28th European Paediatric Rheumatology Congress (PReS 2022)36
COVID-19 and what pediatric rheumatologists should know: a review from a highly affected country33
Failure of anti Interleukin-1 β monoclonal antibody in the treatment of recurrent pericarditis in two children32
Global prevalence estimates of three chronic musculoskeletal conditions: club foot, juvenile idiopathic arthritis and juvenile systemic lupus erythematosus30
Intravenous administration of anakinra in children with macrophage activation syndrome27
Type 1 interferonopathy presenting as juvenile idiopathic arthritis with interstitial lung disease: report of a new phenotype26
Distinguishing active pediatric COVID-19 pneumonia from MIS-C26
Growth and puberty in children with juvenile idiopathic arthritis25
Neurological involvement in Kawasaki disease: a retrospective study24
Telemedicine in pediatric rheumatology: this is the time for the community to embrace a new way of clinical practice24
COVID-19 and myositis; true dermatomyositis or prolonged post viral myositis?21
Post SARS-CoV-2 infection reactive arthritis: a brief report of two pediatric cases21
NLRP12-associated systemic autoinflammatory diseases in children21
Proceedings of the 27th European Paediatric Rheumatology Congress (PReS 2021)19
JAK inhibitors: a potential treatment for JDM in the context of the role of interferon-driven pathology18
0.043584108352661